CASPS
A phase II trial of cediranib in the treatment of patients with alveolar soft part sarcoma.
Disease site: Sarcoma
Treatment modality: Systemic therapy
Status: In follow-up
Trial details
CASPS is a two-arm, randomised, double blind, international, multicentre phase II trial to confirm the ability of the anti-angiogenic drug cediranib to halt disease progression in patients with metastatic alveolar soft part sarcoma.
Thirty-six patients will be recruited from 12 sites in the UK, Australia and Spain over a five-year period. Patients will receive either cediranib or placebo until 24 weeks post-randomisation, when treatment will be unblinded and all patients on placebo and those who have not progressed on active treatment will begin or continue taking cediranib. Treatment will continue until objective disease progression and participants will be followed up for life.
Further information
Chief Investigator: Professor Ian Judson, The Royal Marsden NHS Foundation Trust
ICR-CTSU Scientific Lead: Professor Judith Bliss
Trial management contact: [email protected]
ISRCTN: 63733470
Sponsor: The Institute of Cancer Research
Funding: Cancer Research UK (CRUK/10/021), AstraZenenca
View CASPS on the National Institute for Health Research website: NIHR - Be Part Of Research
Patient friendly information is available from the following link:
CancerHelp UK
Publications and presentations
Judson I, Snowdon C, Fox L, Kernaghan S, Morden J, Bliss J; on behalf of the CASPS Trial Management Group. Trial in progress: a phase II, international trial of cediranib in the treatment of patients with alveolar soft part sarcoma (CASPS) C2130/A12118. Presented at: 10th National Cancer Research Institute Cancer Conference; 2014 Nov 2-5; Liverpool, UK.
Judson I, Snowdon C, Fox L, Kernaghan S, Morden J, Bliss J; on behalf of the CASPS Trial Management Group. Trial in progress: a phase II international trial of cediranib in the treatment of patients with alveolar soft part sarcoma (CASPS) C2130/A12118. Presented at: British Sarcoma Group Conference; 2014 Feb 26-28; Nottingham, UK.
Judson I, Olmos D, Snowdon C, Fox L, Kernaghan S, Morden J, Bliss J; on behalf of the CASPS Trial Management Group. Trial in progress: a phase II international trial of cediranib in the treatment of patients with aveolar soft part sarcoma (CASPS) CRUK ref: C2130/A12118. Presented at: British Sarcoma Group Conference; 2012 Feb 29-Mar 2; Oxford, UK.
Judson I, Morden J P, Kilburn L, Leahy M, Benson C, Bhadri V, Campbell-Hewson Q, Cubedo R, Dangoor A, Fox L, Hennig I, Jarman K, Joubert W, Kernaghan S, Pousa A L, McNeil C, Seddon B, Snowdon C, Tattersall M, Toms C, Trufero J M, Bliss J M - Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial